These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 21053280)

  • 1. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer.
    Chen J; Huang XF; Katsifis A
    J Cell Biochem; 2010 Dec; 111(5):1082-6. PubMed ID: 21053280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.
    Oikonomou E; Pintzas A
    Anticancer Res; 2006; 26(2A):1077-84. PubMed ID: 16619509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
    Shimodaira H; Soeda H; Komine K; Ishioka C
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1063-6. PubMed ID: 19620792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
    Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
    Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational quantification of global effects induced by mutations and drugs in signaling networks of colorectal cancer cells.
    Sommariva S; Caviglia G; Ravera S; Frassoni F; Benvenuto F; Tortolina L; Castagnino N; Parodi S; Piana M
    Sci Rep; 2021 Oct; 11(1):19602. PubMed ID: 34599254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of resistance to anti-EGFR therapy in colorectal cancer.
    Shaib W; Mahajan R; El-Rayes B
    J Gastrointest Oncol; 2013 Sep; 4(3):308-18. PubMed ID: 23997942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attractor landscape analysis of colorectal tumorigenesis and its reversion.
    Cho SH; Park SM; Lee HS; Lee HY; Cho KH
    BMC Syst Biol; 2016 Oct; 10(1):96. PubMed ID: 27765040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB2 emerges as a new target for colorectal cancer.
    Pectasides E; Bass AJ
    Cancer Discov; 2015 Aug; 5(8):799-801. PubMed ID: 26243861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer: Liquid biopsy enables real-time monitoring of molecular alterations in CRC.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Jul; 12(7):372. PubMed ID: 26077554
    [No Abstract]   [Full Text] [Related]  

  • 12. [Melatonin in complex treatment for colorectal cancer patients].
    Pliss MM
    Vopr Onkol; 2016; 62(3):413-7. PubMed ID: 30462903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Heterogeneity of MED23 Gene in Colorectal Cancers.
    Jo YS; Kim MS; Lee SH; Yoo NJ
    Pathol Oncol Res; 2015 Sep; 21(4):1281-2. PubMed ID: 26152846
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: Signalling pathways in anti-cancer drug resistance.
    Chen C; Chen J; Zhao KN
    Curr Med Chem; 2014; 21(26):3007-8. PubMed ID: 25106557
    [No Abstract]   [Full Text] [Related]  

  • 15. Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios.
    Aprile G; Rihawi K; Scartozzi M; Bordonaro R
    Future Oncol; 2015 Oct; 11(19):2625-2628. PubMed ID: 26357968
    [No Abstract]   [Full Text] [Related]  

  • 16. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
    Nat Med; 2015 Jul; 21(7):827. PubMed ID: 26151329
    [No Abstract]   [Full Text] [Related]  

  • 17. [Colorectal cancer targeted therapy].
    Shen Y; Shi Y; Han X
    Zhonghua Bing Li Xue Za Zhi; 2015 Jun; 44(6):430-3. PubMed ID: 26704848
    [No Abstract]   [Full Text] [Related]  

  • 18. Next-generation patient models for colorectal cancer research.
    Nat Biotechnol; 2024 Jul; ():. PubMed ID: 38956327
    [No Abstract]   [Full Text] [Related]  

  • 19. Antioxidant and antiproliferative activity of
    Sheik A; Kim E; Adepelly U; Alhammadi M; Huh YS
    Saudi J Biol Sci; 2023 Apr; 30(4):103609. PubMed ID: 36970255
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.